Reverse Translation of First Generation Clinical PARP Inhibitors to Inform Next Generation PARPi-Based Medicines
Time: 9:00 am
day: Day One
Details:
• Understanding key aspects of PARPi MoA: PARP selectivity, trapping characteristics and HRD-specificity
• Exploring additional PARPi characteristics that contribute towards clinical tolerability profiles (such as secondary pharmacology and plasma vs bone marrow distribution)
